Skip to content 
For decades, medications such as SSRIs and SNRIs have been among the most common treatments for depression.
Then ketamine entered the mental-health conversation.
It has a complicated reputation because the same drug has been used as an anesthetic, misused recreationally, and studied at lower doses as a rapid-acting treatment for depression.
So is ketamine just another antidepressant?
Not exactly.
Traditional antidepressants and IV ketamine differ in several important ways, including:
- The brain systems they affect
- How they are administered
- How quickly antidepressant effects may appear
- How often they are taken
- Their FDA approval status
- Their side effects and monitoring requirements
- How much we know about long-term treatment
The strongest evidence for IV ketamine is currently in treatment-resistant depression, particularly among patients who have not experienced enough improvement from conventional treatments. Randomized clinical trials have demonstrated antidepressant effects within hours to a day after IV ketamine in some patients, although responses vary and may fade without additional treatment.
Here’s how IV ketamine actually compares with traditional antidepressants.
Table of Contents
Quick Answer: IV Ketamine vs Traditional Antidepressants
The simplest difference is that they affect the brain through different pharmacologic pathways.
Many commonly prescribed antidepressants work primarily through the monoamine system.
For example:
SSRIs affect serotonin signaling.
SNRIs affect serotonin and norepinephrine signaling.
IV ketamine works differently.
Ketamine is an NMDA receptor antagonist within the brain’s glutamatergic system. Its antidepressant effects are thought to involve downstream changes in glutamate signaling, including AMPA-receptor activity and pathways involved in synaptic plasticity. The complete antidepressant mechanism is still being investigated.
Another major difference is speed.
Traditional antidepressants generally require ongoing daily treatment, and determining whether a particular medication is effective may take several weeks.
In randomized trials of treatment-resistant depression, some patients receiving IV ketamine experienced significant improvement within several hours to 24 hours.
That does not mean ketamine works instantly for everyone, permanently eliminates depression, or is automatically superior to conventional antidepressants.
It is a different treatment option with a different mechanism, treatment schedule, evidence base, and risk profile.
Watch: Why Ketamine Works Differently From Traditional Antidepressants
Video Transcript
Would you believe me if I told you that ketamine, yes, that ketamine, can be one of the most effective treatments for anxiety and depression?
I know what you’re thinking.
Isn’t that a party drug?
Isn’t that what they use on horses?
And yeah, ketamine has got a bit of a reputation.
But here’s what most people don’t know.
Ketamine has actually been used safely in medicine since the 1960s. It’s been FDA-approved as an anesthetic for a long time.
But what’s new is that we now understand what it can do to the brain at lower, more controlled doses, and it’s remarkable.
Most antidepressants, SSRIs, SNRIs, they target serotonin, and they can work for a lot of people.
But about 50% of people with depression that try antidepressants, they don’t work and can sometimes make things worse.
Ketamine works on a completely different system.
It targets glutamate, which is your brain’s most active neurotransmitter, and it triggers something called neuroplasticity.
The brain starts forming new neural connections within hours, not just weeks or months.
And here’s what surprises most people.
These pathways stick.
It’s not just feeling better when you’re here and the drug is in your system.
The brain is actively reprogramming the way it processes emotion, stress, and thought patterns.
Important Context About the Video
The video communicates several legitimate differences between ketamine and conventional antidepressants, but there are a few areas where the science deserves additional context.
Ketamine has been used medically for decades.
Ketamine was developed during the 1960s and received FDA approval as an anesthetic in 1970.
FDA-approved injectable ketamine remains indicated for anesthesia.
IV ketamine is not FDA-approved for depression, anxiety, PTSD, or another psychiatric condition. Its psychiatric use is off-label. FDA reiterated that distinction in June 2026.
The “50% of antidepressants don’t work” statement is too simplified.
Traditional antidepressants absolutely do not work adequately for everyone.
But there is no single universal 50% failure rate that applies to every antidepressant and every patient.
In the large STAR*D depression trial, approximately one-third of participants achieved remission during the first treatment step with citalopram. Patients who did not remit could proceed through additional treatment strategies.
That shows a major need for additional treatment options without implying that conventional antidepressants broadly fail half of all patients.
Glutamate is the correct term.
Glutamate is the brain’s principal excitatory neurotransmitter.
Ketamine acts as an antagonist at NMDA-type glutamate receptors.
Its antidepressant effects are more complicated than simply “increasing glutamate,” and the complete mechanism is still being studied.
Neuroplasticity is real, but “reprogramming the brain” is a metaphor.
Research supports ketamine-related effects on pathways involved in synaptic plasticity.
That does not mean scientists can currently say that ketamine permanently “rewires” or “reprograms” a patient’s emotional circuitry after an infusion.
The rapid biological changes are an important area of research, but their exact relationship to lasting antidepressant response is still being investigated.
“It genuinely saved my life” is a personal experience.
That statement describes the speaker’s own experience and should be understood as a testimonial, not a guarantee of how another patient will respond.
1. What Are Traditional Antidepressants?
“Antidepressant” describes several medication classes.
Two of the most commonly discussed are:
SSRIs
Selective serotonin reuptake inhibitors include medications such as:
- Escitalopram
- Sertraline
- Fluoxetine
- Citalopram
They primarily increase serotonin availability by inhibiting its reuptake.
SNRIs
Serotonin-norepinephrine reuptake inhibitors include medications such as:
- Venlafaxine
- Duloxetine
- Desvenlafaxine
They influence both serotonin and norepinephrine signaling.
There are also several other antidepressant classes with different mechanisms.
So it would be inaccurate to say:
“All antidepressants work through serotonin.”
The common theme is that most conventional antidepressants work differently from ketamine.
2. What Is IV Ketamine Therapy?
Ketamine is a dissociative anesthetic.
At anesthetic doses, it has been used medically for decades.
Researchers later discovered that lower, subanesthetic doses could produce rapid antidepressant effects in some people with treatment-resistant depression.
One landmark randomized trial administered a single IV ketamine infusion to adults with treatment-resistant major depression.
Twenty-four hours later, patients who received ketamine demonstrated significantly greater improvement in depression scores than patients receiving the active placebo midazolam.
The response rate at 24 hours was:
64% with ketamine
versus
28% with midazolam.
That study helped establish one of ketamine’s most notable characteristics:
its potential speed of antidepressant action.
3. Serotonin and Norepinephrine vs Glutamate
This is the biggest biological difference between ketamine and many traditional antidepressants.
Traditional Antidepressants
SSRIs and SNRIs influence monoamine neurotransmitters.
Those include:
- Serotonin
- Norepinephrine
These medications change neurotransmitter availability relatively quickly.
However, the clinical antidepressant response often develops more gradually, suggesting that downstream changes in neural circuits are important too.
Ketamine
Ketamine acts primarily as an antagonist at the:
N-methyl-D-aspartate, or NMDA, receptor.
NMDA receptors are activated by glutamate.
Glutamate is the major excitatory neurotransmitter in the central nervous system.
Ketamine’s antidepressant mechanism appears to involve a cascade of downstream effects rather than simply blocking one receptor and immediately eliminating depression.
4. What Does Ketamine Do to NMDA Receptors?
Ketamine blocks NMDA receptors.
That alters glutamate signaling within neural networks.
Researchers believe its antidepressant effects may involve downstream enhancement of AMPA receptor signaling and pathways associated with synaptic function and plasticity.
Exactly which pathways are necessary for the clinical antidepressant response continues to be investigated.
That is important because you may see extremely confident online explanations such as:
“Ketamine works because it creates new synapses.”
The science is more complicated.
Ketamine affects multiple molecular and neural systems, and researchers still debate which mechanisms are most important for its antidepressant effect.
5. What Does Neuroplasticity Mean?
Neuroplasticity is the brain’s ability to change in response to experience, activity, injury, learning, and other biological influences.
It can involve:
- Changes in synaptic strength
- Formation or modification of neural connections
- Changes in network activity
- Learning
- Adaptation
Depression has been associated with abnormalities in several neural circuits and synaptic processes.
One theory behind ketamine treatment is that its effects on glutamate-related pathways may temporarily create conditions that support greater synaptic plasticity.
This is where phrases like:
“rewiring the brain”
come from.
They can be useful analogies.
But they should not be interpreted literally as:
one infusion permanently creating a new brain.
6. How Quickly Can IV Ketamine Work?
This is where ketamine differs dramatically from conventional oral antidepressant treatment.
In a landmark National Institute of Mental Health randomized trial, antidepressant improvement following a single IV ketamine infusion was measurable within approximately two hours.
The difference from placebo remained significant at 24 hours and through several subsequent assessments.
Another randomized trial involving 73 patients with treatment-resistant depression found significantly greater improvement 24 hours after ketamine compared with midazolam.
A larger dose-ranging randomized trial likewise demonstrated rapid antidepressant effects following subanesthetic IV ketamine.
So it is reasonable to describe ketamine as a:
rapid-acting antidepressant treatment.
But rapid does not mean guaranteed.
Some patients respond strongly.
Some respond partially.
Some do not respond.
7. How Long Do Traditional Antidepressants Take to Work?
Traditional antidepressants are generally taken every day.
Patients often need several weeks of treatment before clinicians can adequately assess response, particularly because medication may also require gradual dose adjustment.
That creates one of the practical challenges of conventional depression treatment.
A patient may need to:
- Start medication
- Wait for therapeutic effects
- Adjust the dose
- Monitor side effects
- Determine whether symptoms improved enough
- Switch or augment treatment if response is inadequate
The STAR*D trial was designed around this reality.
Participants could move through multiple treatment steps when remission was not achieved with the initial antidepressant.
Ketamine’s rapid action therefore represents a fundamentally different treatment timeline.
8. Does Ketamine Work When Antidepressants Have Failed?
This is where much of the strongest IV ketamine research has focused.
Treatment-resistant depression, or TRD, generally refers to depression that has not adequately improved despite appropriate conventional treatment attempts, although exact definitions can vary between studies and clinical settings.
Several major IV ketamine randomized trials specifically recruited patients with treatment-resistant depression.
That is important.
It means much of ketamine’s evidence base is not based on replacing an SSRI as the first treatment for every newly diagnosed person.
It is particularly relevant to patients who have already tried conventional treatment without sufficient improvement.
9. Why Don’t Antidepressants Work for Everyone?
Depression is not one simple chemical deficiency.
Patients diagnosed with major depressive disorder can differ enormously in:
- Genetics
- Symptoms
- Trauma history
- Sleep
- Medical conditions
- Medication response
- Anxiety
- Cognitive symptoms
- Brain circuitry
- Social environment
- Other biological factors
That helps explain why one medication may work extremely well for one person and poorly for another.
STAR*D demonstrated this clearly.
Approximately one-third of patients achieved remission during the initial citalopram treatment step, while many required additional treatment strategies. The chance of remission generally became lower after multiple unsuccessful treatment steps.
This does not mean antidepressants are ineffective.
It means depression treatment often requires individualization.
10. How Long Do Ketamine’s Antidepressant Effects Last?
This is one of the biggest differences between:
rapid response
and
long-term remission.
A single ketamine treatment can produce rapid improvement, but that response may fade.
In an early randomized study, significant improvement occurred rapidly after treatment and some patients maintained response through one week, but many did not.
Researchers therefore began studying repeated treatment.
A randomized trial evaluating repeated IV ketamine found that two or three infusions per week could help sustain antidepressant effects during an acute treatment period.
Another study evaluated:
- A single ketamine infusion
- A six-infusion acute series
- Maintenance infusions
to examine how repeated treatment might prolong response.
The practical takeaway is:
Ketamine should not be presented as a one-time permanent cure for depression.
Some patients may need an initial series, maintenance treatment, other psychiatric care, psychotherapy, medication, or a combination of approaches.
11. Daily Medication vs Intermittent Infusions
Traditional antidepressants and IV ketamine also create very different treatment experiences.
Traditional Antidepressants
Usually:
- Taken at home
- Taken every day
- Require relatively little time per dose
- May continue for months or years
- Require periodic prescribing follow-up
IV Ketamine
Generally involves:
- Treatment at a clinic
- IV placement
- A controlled infusion
- Monitoring during treatment
- Recovery before leaving
- Transportation considerations because patients should not simply drive immediately after treatment
At The Re/ Clinic in Sandy, Utah, IV ketamine treatment is administered in a medically supervised clinical setting.
The experience is therefore substantially different from taking an oral antidepressant at home each morning.
12. What Does a Ketamine Treatment Feel Like?
At subanesthetic doses, patients may experience temporary changes in:
- Perception
- Awareness
- Sense of time
- Sense of body
- Thought patterns
- Emotional processing
Dissociation is one of ketamine’s well-recognized effects.
Some people find the experience relaxing or meaningful.
Others may experience it as unfamiliar or uncomfortable.
The subjective experience is not identical to the antidepressant effect, and researchers continue to investigate exactly how much dissociation itself contributes to therapeutic response.
13. Side Effects: Ketamine vs Traditional Antidepressants
Neither treatment is free of potential side effects.
Traditional Antidepressants
Potential adverse effects vary by medication and may include:
- Nausea
- Gastrointestinal symptoms
- Headache
- Sleep changes
- Sexual side effects
- Changes in appetite
- Activation or anxiety
- Discontinuation symptoms if some medications are stopped abruptly
The exact side-effect profile depends heavily on the specific drug.
Ketamine
During or shortly after an infusion, possible effects can include:
- Dissociation
- Dizziness
- Nausea
- Perceptual changes
- Temporary increases in blood pressure
- Sedation
Ketamine is also a controlled substance with abuse and misuse potential.
That is one reason appropriate medical screening, dosing, supervision, and monitoring matter.
14. Is Ketamine Addictive?
Ketamine is a Schedule III controlled substance, and FDA specifically recognizes its potential for abuse and misuse.
That does not mean a medically supervised patient receiving intermittent therapeutic infusions will develop addiction.
It does mean:
“Ketamine cannot be addictive” is not accurate.
Medical use and recreational misuse involve very different circumstances, but ketamine’s abuse potential should still be part of an informed discussion.
15. Is IV Ketamine FDA-Approved for Depression?
No.
This distinction is extremely important.
Injectable ketamine is FDA-approved as an anesthetic.
FDA stated again in June 2026 that ketamine is not FDA-approved for the treatment of any psychiatric disorder.
When IV ketamine is administered for depression, it is an:
off-label use.
Off-label prescribing is common throughout medicine and does not automatically mean a treatment is inappropriate.
It does mean the use itself has not received FDA approval for that indication.
16. What About Esketamine, or Spravato?
Ketamine and esketamine are related, but they are not interchangeable.
Ketamine contains two mirror-image forms of the molecule.
Esketamine is one of those forms.
FDA-approved esketamine is marketed as Spravato, a nasal spray with specific psychiatric indications.
Unlike off-label IV ketamine for depression, Spravato has gone through FDA review for its approved psychiatric uses.
It is also subject to a Risk Evaluation and Mitigation Strategy, or REMS, because of risks including:
- Sedation
- Dissociation
- Respiratory depression
- Abuse and misuse
Patients must receive Spravato in an appropriately certified healthcare setting and undergo monitoring after administration.
So:
IV ketamine ≠ intranasal esketamine.
17. Does Ketamine Treat Anxiety?
Ketamine has also been researched for anxiety symptoms and anxiety disorders.
However, the evidence base is not as established as the evidence for treatment-resistant depression.
IV ketamine is not FDA-approved for anxiety.
This distinction is especially important because the video opens by discussing both anxiety and depression.
A patient with anxiety should not assume:
“Ketamine has rapid antidepressant evidence, therefore it is equally proven for every anxiety disorder.”
Different diagnoses require separate clinical evidence.
18. Can Ketamine Help With Suicidal Thoughts?
Rapid reduction of suicidal thinking has been one particularly important area of ketamine research.
The ability to produce changes on a much faster timeline than conventional antidepressants has made ketamine and esketamine especially interesting in severe depression research.
However, acute suicidal thoughts require an appropriate psychiatric and safety evaluation.
Ketamine should not be viewed as a substitute for emergency mental-health care when someone is in immediate danger.
19. Can You Take Ketamine While Taking an Antidepressant?
Sometimes.
Ketamine treatment does not necessarily require patients to discontinue their existing antidepressant.
Treatment plans vary according to:
- Current medications
- Diagnosis
- Treatment response
- Medical history
- Psychiatric history
- Other medications or substances
This should be determined by the treating medical team.
Patients should never stop a psychiatric medication abruptly because they are considering ketamine.
20. Does Ketamine Replace Therapy?
Not necessarily.
Medication and psychotherapy address different aspects of depression treatment.
Some researchers are specifically studying ways psychotherapy might help patients maintain or build upon improvement following ketamine treatment.
For example, a randomized clinical study examined cognitive behavioral therapy following a six-infusion course of IV ketamine in patients with treatment-resistant depression.
The broader principle is important:
Ketamine does not have to be viewed as ketamine versus therapy.
For some patients, it may become one component of a larger treatment plan.
21. Which Is Better: Ketamine or an SSRI?
There is no universal answer.
For a patient experiencing a first episode of uncomplicated depression, conventional antidepressant medication and psychotherapy may be entirely appropriate.
For someone who has already tried multiple adequate antidepressant treatments without sufficient improvement, a rapid-acting intervention such as ketamine may become a different conversation.
The decision can depend on:
- Diagnosis
- Depression severity
- Previous treatments
- Response to previous medications
- Side effects
- Suicidal symptoms
- Medical history
- Substance-use history
- Cost and access
- Patient preferences
Ketamine should therefore not be marketed as:
“better than antidepressants.”
A more useful question is:
“Is a treatment that works through a different biological pathway appropriate for this particular patient?”
22. Is Ketamine Only for People Who Have Failed Every Other Treatment?
Not necessarily every imaginable treatment.
But much of the strongest IV ketamine research has specifically involved patients with treatment-resistant depression.
That makes treatment history an important part of the evaluation.
A good consultation should discuss:
- What medications have been tried
- At what doses
- For how long
- Whether psychotherapy has been tried
- Whether the diagnosis is accurate
- What symptoms remain
- Whether another medical or psychiatric condition may be contributing
The goal should not be to rush someone toward an infusion.
It should be to determine whether ketamine makes sense within the larger treatment plan.
Frequently Asked Questions
Is ketamine an antidepressant?
Ketamine is FDA-approved as an anesthetic, not as an antidepressant.
However, subanesthetic IV ketamine has demonstrated rapid antidepressant effects in randomized trials involving treatment-resistant depression.
Its psychiatric use by IV is off-label.
Is IV ketamine FDA-approved for depression?
No.
FDA-approved injectable ketamine is indicated for anesthesia.
FDA reiterated in 2026 that ketamine itself is not approved for any psychiatric disorder.
Is Spravato the same thing as IV ketamine?
No.
Spravato contains esketamine and is administered as a nasal spray.
It has FDA-approved psychiatric indications and is administered under a restricted REMS program.
IV racemic ketamine is a different treatment and is used off-label when administered for depression.
Does ketamine increase serotonin?
Ketamine’s primary pharmacological action differs from SSRIs.
It antagonizes NMDA-type glutamate receptors and affects downstream glutamatergic signaling.
That does not mean serotonin has absolutely no involvement in ketamine’s broader neurobiology. Human research suggests its mechanism may involve multiple interacting neurotransmitter systems.
Does ketamine work through glutamate?
Yes.
Ketamine acts within the glutamatergic system, particularly through NMDA-receptor antagonism.
Glutamate is the brain’s primary excitatory neurotransmitter.
Does ketamine rewire your brain?
“Rewiring” is an analogy.
Ketamine affects biological pathways involved in synaptic plasticity, but saying it permanently rewires the brain after an infusion is stronger than current evidence supports.
How quickly can ketamine help depression?
Randomized trials have demonstrated antidepressant effects within hours and significant differences at approximately 24 hours in some patients with treatment-resistant depression.
Not every patient responds.
How long do ketamine results last?
It varies.
The antidepressant effect after a single infusion may diminish over days or weeks.
Research has therefore evaluated repeated acute treatments and maintenance infusions.
Why do antidepressants take longer than ketamine?
SSRIs and SNRIs work through different neurotransmitter systems and downstream biological processes.
Although they alter neurotransmitter availability relatively quickly, clinical antidepressant improvement usually develops over a longer treatment period.
Ketamine’s glutamate-related effects can produce a much more rapid antidepressant response in some patients.
What percentage of people don’t respond to antidepressants?
There is no single percentage that applies to every medication and patient.
In STAR*D, approximately one-third of participants reached remission during the initial treatment step with citalopram. Many required subsequent treatment strategies.
Does ketamine work if SSRIs didn’t?
It can for some patients.
Major IV ketamine studies have specifically demonstrated rapid antidepressant effects among people with treatment-resistant depression who had previously experienced inadequate responses to conventional treatment.
It still does not work for everyone.
Is ketamine safer than antidepressants?
They have different risks.
Traditional antidepressants and ketamine have different side-effect profiles, administration methods, abuse potential, and monitoring requirements.
Neither should simply be labeled universally safer.
Is ketamine addictive?
Ketamine has recognized abuse and misuse potential and is classified as a Schedule III controlled substance.
Medical administration in a supervised setting differs significantly from recreational misuse, but its abuse potential should not be dismissed.
Can ketamine be used with antidepressants?
In some treatment plans, yes.
Patients should discuss all psychiatric medications with their treating providers and should not stop an antidepressant abruptly because they are considering ketamine.
Different Pathways, Different Tools
Depression treatment is not a competition between:
ketamine
and
antidepressants.
For millions of people, conventional antidepressants are useful treatments.
But they do not provide adequate relief for everyone.
Ketamine became so important to depression research partly because it demonstrated that antidepressant effects could be produced through a very different biological pathway and on a much faster timeline than clinicians traditionally expected.
That does not make it a miracle treatment.
It makes it another tool.
At The Re/ Clinic in Sandy, Utah, IV ketamine therapy is provided in a medically supervised environment for appropriately evaluated patients.
If you have tried antidepressants or other treatments and continue to struggle with depression symptoms, a consultation can help determine whether IV ketamine is an appropriate option to discuss as part of your overall mental-health treatment plan.
Call: 385-240-1000
Location: 9035 S 700 E, Sandy, UT 84070
References
- Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. American Journal of Psychiatry. 2013. In 73 adults with treatment-resistant depression, a single IV ketamine infusion produced significantly greater improvement than midazolam at 24 hours.
- Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry. 2006. Demonstrated rapid antidepressant effects after a single IV ketamine infusion, with onset within approximately two hours in some patients.
- Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. American Journal of Psychiatry. 2016. Evaluated repeated twice- and three-times-weekly IV ketamine treatment.
- Phillips JL, Norris S, Talbot J, et al. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. American Journal of Psychiatry. 2019. Evaluated single, repeated, and maintenance IV ketamine treatment.
- Rush AJ, et al. STARD: revising conventional wisdom.* Review of the large STAR*D effectiveness study. Approximately one-third of participants remitted during first-step citalopram treatment, illustrating the need for additional treatment strategies in many patients.
- Rush AJ, et al. What did STARD teach us?* Reviews outcomes across sequential depression-treatment steps and declining remission likelihood after unsuccessful treatments.
- U.S. Food and Drug Administration. Current 2026 regulatory information confirms that injectable ketamine is FDA-approved as an anesthetic and is not FDA-approved for treatment of psychiatric disorders.
- U.S. Food and Drug Administration. Current labeling information for Spravato, or esketamine, including psychiatric indications and REMS-related requirements.
- Tiger M, et al. A randomized placebo-controlled PET study of ketamine’s effect on serotonin 1B receptor binding in patients with SSRI-resistant depression. Translational Psychiatry. 2020. Demonstrates the complexity of ketamine’s mechanism beyond a simple single-neurotransmitter explanation.